12.42
0.30 (2.48%)
| Penutupan Terdahulu | 12.12 |
| Buka | 12.01 |
| Jumlah Dagangan | 1,657,550 |
| Purata Dagangan (3B) | 2,446,830 |
| Modal Pasaran | 911,846,528 |
| Harga / Jualan (P/S) | 2.95 |
| Harga / Buku (P/B) | 1.44 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Keuntungan | -10.92% |
| Margin Operasi (TTM) | 37.82% |
| EPS Cair (TTM) | -0.660 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 646.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.59% |
| Nisbah Semasa (MRQ) | 4.58 |
| Aliran Tunai Operasi (OCF TTM) | -250.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.69 M |
| Pulangan Atas Aset (ROA TTM) | -5.39% |
| Pulangan Atas Ekuiti (ROE TTM) | -7.34% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Arvinas, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.25 |
|
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.89% |
| % Dimiliki oleh Institusi | 90.98% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| New Leaf Venture Partners, L.L.C. | 30 Sep 2025 | 1,585,721 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 16.00 (Barclays, 28.82%) | Beli |
| Median | 15.00 (20.77%) | |
| Rendah | 6.00 (Goldman Sachs, -51.69%) | Jual |
| Purata | 13.20 (6.28%) | |
| Jumlah | 4 Beli, 1 Jual | |
| Harga Purata @ Panggilan | 10.12 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Stephens & Co. | 10 Nov 2025 | 15.00 (20.77%) | Beli | 11.19 |
| 18 Sep 2025 | 14.00 (12.72%) | Beli | 7.72 | |
| Barclays | 06 Nov 2025 | 16.00 (28.82%) | Beli | 10.00 |
| 17 Sep 2025 | 16.00 (28.82%) | Beli | 7.61 | |
| Wells Fargo | 06 Nov 2025 | 15.00 (20.77%) | Beli | 10.00 |
| BTIG | 30 Oct 2025 | 14.00 (12.72%) | Beli | 9.93 |
| 18 Sep 2025 | 10.00 (-19.48%) | Beli | 7.72 | |
| Goldman Sachs | 15 Oct 2025 | 6.00 (-51.69%) | Jual | 9.46 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |